Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Albany Molecular To Buy Oso Biopharma

by Marc S. Reisch
June 9, 2014 | A version of this story appeared in Volume 92, Issue 23

Albany Molecular Research Inc. has signed a definitive agreement to buy Albuquerque, N.M.-based Oso Biopharmaceuticals Manufacturing for $110 million. Pending regulatory approvals, the deal should close by the end of September. Oso is a contract maker of injectable drug products that on its own would have had 2014 earnings of $10 million on sales of $60 million. AMRI says Oso will add significantly to its sterile-manufacturing capability.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.